Atlanta, GA, United States of America

Richard Charles Turek

This inventor holds 12 USPTO granted patents, plus 3 CIPO patents and 3 EPO patents. Top assignees: Novartis Ag, Ciba-Geigy Corporation. Active years: 1993-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Charles Turek. Retrieved from https://idiyas.com/inventor/richard-charles-turek

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 91.7


 

Average Co-Inventor Count = 3.0

ph-index = 6

Forward Citations = 178(Granted Patents)


Company Filing History:


Years Active: 1993-2015

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Richard Charles Turek: Pioneering Inventor from Atlanta, GA

Introduction: Richard Charles Turek is a distinguished inventor based in Atlanta, Georgia, known for his groundbreaking contributions to various fields.

Latest Patents: Richard Charles Turek holds several patents in the areas of technology, healthcare, and consumer products, showcasing his versatility and innovative spirit.

Career Highlights: With a career spanning over two decades, Turek has consistently pushed the boundaries of innovation, leading to the development of cutting-edge solutions that have impacted industries worldwide.

Collaborations: Throughout his career, Richard Charles Turek has collaborated with leading companies, research institutions, and universities to bring his inventions to life, fostering a culture of creativity and excellence.

Conclusion: Richard Charles Turek's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors, making him a true pioneer in the world of patents and inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…